Disc Medicine, Inc. (NASDAQ:IRON) Insider Pamela Stephenson Sells 3,137 Shares

Disc Medicine, Inc. (NASDAQ:IRON) insider Pamela Stephenson sold 3,137 shares of the business’s stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $54.58, for a total value of $171,217.46. Following the sale, the insider now owns 69,529 shares in the company, valued at approximately $3,794,892.82. The trade was a 4.32 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link.

Disc Medicine Stock Performance

Shares of NASDAQ IRON opened at $54.35 on Friday. The stock’s 50 day moving average price is $59.26 and its two-hundred day moving average price is $55.02. Disc Medicine, Inc. has a 52-week low of $25.60 and a 52-week high of $77.60.

Institutional Investors Weigh In On Disc Medicine

Institutional investors have recently made changes to their positions in the company. Sterling Capital Management LLC lifted its stake in Disc Medicine by 798.4% during the fourth quarter. Sterling Capital Management LLC now owns 566 shares of the company’s stock worth $36,000 after purchasing an additional 503 shares during the last quarter. GF Fund Management CO. LTD. acquired a new stake in shares of Disc Medicine during the fourth quarter worth $40,000. Tower Research Capital LLC TRC lifted its position in shares of Disc Medicine by 47.6% in the 4th quarter. Tower Research Capital LLC TRC now owns 825 shares of the company’s stock worth $52,000 after buying an additional 266 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its position in shares of Disc Medicine by 45.7% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,075 shares of the company’s stock worth $54,000 after buying an additional 337 shares during the last quarter. Finally, Quest Partners LLC acquired a new position in shares of Disc Medicine in the 3rd quarter valued at about $131,000. 83.70% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

IRON has been the subject of a number of recent research reports. Wedbush reissued an “outperform” rating and set a $90.00 price objective (up from $83.00) on shares of Disc Medicine in a research note on Tuesday, January 21st. Stifel Nicolaus boosted their price target on Disc Medicine from $90.00 to $94.00 and gave the stock a “buy” rating in a report on Friday, January 24th. Scotiabank increased their price objective on Disc Medicine from $70.00 to $73.00 and gave the company a “sector outperform” rating in a research note on Wednesday, January 22nd. Morgan Stanley upgraded shares of Disc Medicine from an “equal weight” rating to an “overweight” rating and set a $85.00 target price on the stock in a report on Tuesday, November 5th. Finally, HC Wainwright restated a “buy” rating and set a $118.00 target price on shares of Disc Medicine in a research report on Tuesday, January 21st. Nine research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, Disc Medicine currently has an average rating of “Buy” and an average target price of $88.90.

Disc Medicine Company Profile

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.